siRNA structures for high activity and reduced off target

Patent metadata

Field	Value
Publication number	US-10358647-B2
Application number	US-201615376633-A
Country	US
Kind code	B2
Filing date	Dec 12, 2016
Priority date	Dec 13, 2015
Publication date	Jul 23, 2019
Grant date	Jul 23, 2019

Abstract

This invention provides compounds, compositions and methods for modulating the expression of target genes using RNA interference. RNAi structures and molecules of this invention can be used for modulating or silencing the expression of genes, with high levels of RNAi activity and reduced off target actions. Advantageous structures include siRNAs targeted to any gene having one or more 2′-deoxy nucleotides located in the seed region. The RNA interference molecules can be used in methods for preventing or treating diseases.

First claim

What is claimed is:

1. A siRNA or RNAi nucleic acid molecule, wherein:
a) the molecule has a polynucleotide sense strand and a polynucleotide antisense strand;
b) each strand of the molecule is from 15 to 30 nucleotides in length;
c) a contiguous region of from 15 to 30 nucleotides of the antisense strand is complementary to a sequence of a mRNA;
d) at least a portion of the sense strand is complementary to at least a portion of the antisense strand, and the molecule has a duplex region of from 15 to 30 nucleotides in length, wherein one or more of the nucleotides in the duplex region at positions 3 to 8 from the 5′ end of the antisense strand are deoxynucleotides;
e) wherein the antisense strand has deoxynucleotides in a plurality of positions, the plurality of positions being one of the following:
each of positions 4, 6 and 8, from the 5′ end of the antisense strand;
each of positions 3, 5 and 7, from the 5′ end of the antisense strand;
each of positions 1, 3, 5 and 7, from the 5′ end of the antisense strand;
each of positions 3-8, from the 5′ end of the antisense strand; and
each of positions 5-8, from the 5′ end of the antisense strand; and
f) wherein the molecule is active for modulating expression of the mRNA.

2. The molecule of claim 1 , wherein the molecule is an RNAi molecule active for modulating expression of the mRNA.

3. The molecule of claim 1 , wherein the molecule is active for inhibiting expression of a gene selected from protein coding genes, proto-oncogenes, oncogenes, tumor suppressor genes, and cell signaling genes.

4. The molecule of claim 1 , wherein the mRNA is a human mRNA.

5. The molecule of claim 1 , wherein the molecule has an IC50 for knockdown of the mRNA of less than 100 pM.

6. The molecule of claim 1 , wherein the molecule has an IC50 for knockdown of the mRNA of less than 50 pM.

7. The molecule of claim 1 , wherein the molecule has an IC50 for knockdown of the mRNA of less than 10 pM.

8. The molecule of claim 1 , wherein a single administration of the molecule inhibits the mRNA by at least 25% in vivo.

9. The molecule of claim 1 , wherein each strand of the molecule is from 18 to 22 nucleotides in length.

10. The molecule of claim 1 , wherein the duplex region is 19 nucleotides in length.

11. The molecule of claim 1 , wherein the polynucleotide sense strand and the polynucleotide antisense strand are connected as a single strand, and form a duplex region connected at one end by a loop.

12. The molecule of claim 1 , wherein the molecule has a blunt end.

13. The molecule of claim 1 , wherein the molecule has one or more 3′ overhangs.

14. The molecule of claim 1 , wherein one or more of the nucleotides in the duplex region is chemically-modified.

15. The molecule of claim 14 , wherein the chemically-modified nucleotides are 2′-O-alkyl substituted nucleotides, 2′-deoxy-2′-fluoro substituted nucleotides, phosphorothioate nucleotides, locked nucleotides, or any combination thereof.

16. The molecule of claim 1 , wherein the base sequence of the antisense strand is SEQ ID NOs:157 UAGGGUCUCAAAAGGCUUCNN and the base sequence of the sense strand is SEQ ID NOs:131 GAAGCCUUUUGAGACCCUANN.

17. A pharmaceutical composition comprising the molecule of claim 1 and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17 , wherein the carrier comprises a lipid molecule or liposome.

19. An isolated vector or cell comprising the molecule of claim 1 .

20. The molecule of claim 1 , wherein the antisense strand is SEQ ID NOs:182 fUAGgGuCu C A AA AGGC UU C UU and the sense strand is SEQ ID NOs:156 GAA GCCU U U U GAGACCC UAUU , wherein upper case refers to ribonucleotides, lower case refers to deoxyribonucleotides, f refers to the nucleotide on its right hand side as being 2′-deoxy-2′-fluoro substituted, and underlining refers to a 2′-OMe-substituted nucleotide.

21. A siRNA or RNAi nucleic acid molecule, wherein:
a) the molecule has a polynucleotide sense strand and a polynucleotide antisense strand;
b) each strand of the molecule is from 15 to 30 nucleotides in length;
c) a contiguous region of from 15 to 30 nucleotides of the antisense strand is complementary to a sequence of a mRNA;
d) at least a portion of the sense strand is complementary to at least a portion of the antisense strand, and the molecule has a duplex region of from 15 to 30 nucleotides in length, wherein one or more of the nucleotides in the duplex region at positions 3 to 8 from the 5′ end of the antisense strand are deoxynucleotides;
e) wherein the antisense strand has deoxynucleotides in a plurality of positions, the plurality of positions being one of the following:
each of positions 4, 6 and 8, from the 5′ end of the antisense strand;
each of positions 3, 5 and 7, from the 5′ end of the antisense strand;
each of positions 1, 3, 5 and 7, from the 5′ end of the antisense strand;
each of positions 3-8, from the 5′ end of the antisense strand; and
each of positions 5-8, from the 5′ end of the antisense strand; and
f) wherein the molecule is active for inhibiting expression of a gene selected from protein coding genes, proto-oncogenes, oncogenes, tumor suppressor genes, and cell signaling genes.

Assignees

• Nitto Denko Corp

Inventors

• Minomi Kenjirou
• Harborth Jens
• Cina Cima
• Ying Wenbin
• Zheng Jane
• Vaish Narendra

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C12N2310/343

  having patterns, e.g. ==--==--==-- · CPC title

• C12N15/1137 Primary

  against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

• C12N2310/321

  2'-O-R Modification · CPC title